Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Remimazolam Anesthesia in Patients Undergoing Deep Inferior Epigastric Perforator Flap Reconstruction for Breast Cancer: A Retrospective Cohort Study.

International journal of medical sciences·2026
Same author

Stress Accelerates Depressive-Like Behaviors through Increase of Notch2 Expression in N141I Mutation Presenilin-2 Transgenic Mice.

Biomolecules & therapeutics·2026
Same author

Effect of early exercise on functional recovery and surgical outcomes after post-mastectomy breast reconstruction: study protocol for a randomized clinical trial.

BMC cancer·2026
Same author

Chlamy_ChloroPred: a deep learning-based, highly accurate binary classifier for chloroplast protein prediction in the model microalga, <i>Chlamydomonas reinhardtii</i>, with potential cross-proteome versatility.

Frontiers in microbiology·2026
Same author

COMPARISON OF INITIAL LOADING INJECTION OUTCOMES BETWEEN AFLIBERCEPT 8 MG AND FARICIMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Retina (Philadelphia, Pa.)·2026
Same author

The sugar transporter STP1-driven trophic conversion of Chlamydomonas reinhardtii.

Microbial cell factories·2026
Same journal

Persistent placoid maculopathy: long term outcomes and prognostic factors.

Retina (Philadelphia, Pa.)·2026
Same journal

ANTI-VEGF THERAPY SWITCHING RETINAL DISEASES: Characterizing Clinical Manifestations and Common Involved Genes: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

THE EFFICACY AND SAFETY OF SUBRETINAL BALANCED SALT SOLUTION INJECTION IN DIABETIC MACULAR EDEMA WITH HARD EXUDATES: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

EVALUATING CLINICAL OUTCOMES OF AMNIOTIC MEMBRANE COVERAGE COMBINED WITH EARLY VITRECTOMY IN THE MANAGEMENT OF PERFORATING GLOBE INJURIES.

Retina (Philadelphia, Pa.)·2026
Same journal

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Retina (Philadelphia, Pa.)·2026
Same journal

Severe retinal non-perfusion is associated with fewer retinal lesions on ultra-wide field fundus photography in proliferative diabetic retinopathy.

Retina (Philadelphia, Pa.)·2026
See all related articles

Related Experiment Video

Updated: Feb 21, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.8K

INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION.

Han Joo Cho1, Hyun Ji Hwang, Hyoung Seok Kim

  • 1Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, Seoul, South Korea.

Retina (Philadelphia, Pa.)
|October 7, 2017
PubMed
Summary
This summary is machine-generated.

Intravitreal aflibercept and ranibizumab showed similar visual acuity improvements for Type 3 neovascularization. However, aflibercept treatment led to a higher incidence of geographic atrophy compared to ranibizumab.

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.5K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.6K

Related Experiment Videos

Last Updated: Feb 21, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.8K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.5K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.6K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Neovascularization

Background:

  • Type 3 neovascularization (3N) is a significant cause of vision loss.
  • Anti-vascular endothelial growth factor (anti-VEGF) therapies are standard treatments for neovascular age-related macular degeneration.
  • Comparing aflibercept and ranibizumab for 3N is crucial for treatment selection.

Purpose of the Study:

  • To compare the efficacy of intravitreal aflibercept versus ranibizumab in patients with Type 3 neovascularization.
  • To evaluate visual acuity and anatomical changes after 12 months of treatment.

Main Methods:

  • Retrospective analysis of 63 treatment-naive eyes with Type 3 neovascularization.
  • Patients received either intravitreal aflibercept or ranibizumab.
  • Treatment involved initial monthly loading doses followed by as-needed injections; outcomes assessed at 12 months.

Main Results:

  • Both aflibercept and ranibizumab groups showed significant improvements in best-corrected visual acuity (BCVA) and reductions in central foveal thickness (CFT) at 12 months.
  • No significant difference was observed between the groups in BCVA improvement or CFT reduction.
  • Geographic atrophy occurred significantly more frequently in the aflibercept group (42.9%) than in the ranibizumab group (19.0%).

Conclusions:

  • Intravitreal aflibercept and ranibizumab offer comparable visual and anatomical benefits for Type 3 neovascularization at 12 months.
  • A higher incidence of geographic atrophy was noted with aflibercept treatment.
  • Further research is needed to understand the long-term implications of these findings.